Evidence map›Paper›PMID 30787877›Full record

ArticleFrontiers in pharmacology2019

Evaluation of Riboflavin Transporters as Targets for Drug Delivery and Theranostics.

Lisa Bartmann, David Schumacher, Saskia von Stillfried, Marieke Sternkopf, Setareh Alampour-Rajabi, Marc A M J van Zandvoort, Fabian Kiessling, Zhuojun Wu

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 52 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Lisa BartmannInstitute for Experimental Molecular Imaging, University Clinic, RWTH Aachen University, Aachen, Germany.
David SchumacherInstitute for Molecular Cardiovascular Research, University Clinic, RWTH Aachen University, Aachen, Germany.
Saskia von StillfriedInstitute of Pathology, University Clinic, RWTH Aachen University, Aachen, Germany.
Marieke SternkopfInstitute for Molecular Cardiovascular Research, University Clinic, RWTH Aachen University, Aachen, Germany.
Setareh Alampour-RajabiInstitute for Molecular Cardiovascular Research, University Clinic, RWTH Aachen University, Aachen, Germany.
Marc A M J van ZandvoortInstitute for Molecular Cardiovascular Research, University Clinic, RWTH Aachen University, Aachen, Germany.
Fabian KiesslingInstitute for Experimental Molecular Imaging, University Clinic, RWTH Aachen University, Aachen, Germany.
Zhuojun WuInstitute for Experimental Molecular Imaging, University Clinic, RWTH Aachen University, Aachen, Germany.
RWTH Aachen University · DEMaastricht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The retention and cellular internalization of drug delivery systems and theranostics for cancer therapy can be improved by targeting molecules. Since an increased uptake of riboflavin was reported for various cancers, riboflavin and its derivatives may be promising binding moieties to trigger internalization via the riboflavin transporters (RFVT) 1, 2, and 3. Riboflavin is a vitamin with pivotal role in energy metabolism and indispensable for cellular growth. In previous preclinical studies on mice, we showed the target-specific accumulation of riboflavin-functionalized nanocarriers in cancer cells. Although the uptake mechanism of riboflavin has been studied for over a decade, little is known about the riboflavin transporters and their expression on cancer cells, tumor stroma, and healthy tissues. Furthermore, evidence is lacking concerning the representativeness of the preclinical findings to the situation in humans. In this study, we investigated the expression pattern of riboflavin transporters in human squamous cell carcinoma (SCC), melanoma and luminal A breast cancer samples, as well as in healthy skin, breast, aorta, and kidney tissues. Low constitutive expression levels of RFVT1-3 were found on all healthy tissues, while RFVT2 and 3 were significantly overexpressed in melanoma, RFVT1 and 3 in luminal A breast cancer and RFVT1-3 in SCC. Correspondingly, the SCC cell line A431 was highly positive for all RFVTs, thus qualifying as suitable

Indexed as

cancer therapynanocarrierRFVTriboflavintargeting moleculestheranostic

Identifiers

PMID30787877
PMCPMC6372557
OpenAlexW2912338091

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.